Koyfin Home > Directory > Health Care > Kindred Biosciences > Cash from Financing Activities

Kindred Biosciences Cash from Financing Activities Chart (KIN)

Kindred Biosciences annual/quarterly Cash from Financing Activities from 2013 to 2020.
  • Kindred Biosciences Cash from Financing Activities for the quarter ending June 06, 2020 was $0m a -14,040.88% decrease of -19m year over year
  • Kindred Biosciences Cash from Financing Activities for the last 12 months ending June 06, 2020 was $20m a -224.70% decrease of -44m year over year
  • Kindred Biosciences Annual Cash from Financing Activities for 2019 was $64m a 21.81% increase of 14m from 2018
  • Kindred Biosciences Annual Cash from Financing Activities for 2018 was $50m a -5.51% decrease of -3m from 2017
  • Kindred Biosciences Annual Cash from Financing Activities for 2017 was $53m a 99.69% increase of 53m from 2016
Other Cash Flow Metrics:
  • Kindred Biosciences Cash Flow from Operations for the quarter ending December 12, 2018 was $-13m a 12.86% decrease of -2m year over year
  • Kindred Biosciences Levered Free Cash Flow (FCF) for the quarter ending December 12, 2018 was $-16m a 50.99% decrease of -8m year over year
  • Kindred Biosciences Total Revenue for the quarter ending September 09, 2018 was $1m
View Chart On Koyfin

Quarterly KIN Cash from Financing Activities Data

06/2020$0m
03/2020$-1m
12/2019$1m
09/2019$19m
06/2019$1m
03/2019$43m
12/2018$1m
09/2018$0m
06/2018$49m
03/2018$0m

Annual KIN Cash from Financing Activities Data

2019$64m
2018$50m
2017$53m
2016$0m
2015$0m
2014$58m
2013$66m
2012$4m